Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Adam Jacob Schoenfeld, Kathryn Cecilia Arbour, Hira A. Rizvi et al. · Annals of Oncology · 2019

Cited by 404 works. doi:10.1093/annonc/mdz077 Open-access PDF

Authors

References